Multifarious Biologic Loaded Liposomes that Stimulate the Mammalian Target of Rapamycin Signaling Pathway Show Retina Neuroprotection after Retina Damage by Eriksen, Anne Zebitz et al.
 
 
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright 
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
 Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
 You may not further distribute the material or use it for any profit-making activity or commercial gain 
 You may freely distribute the URL identifying the publication in the public portal 
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
  
 
   
 
 
Downloaded from orbit.dtu.dk on: Mar 29, 2019
Multifarious Biologic Loaded Liposomes that Stimulate the Mammalian Target of
Rapamycin Signaling Pathway Show Retina Neuroprotection after Retina Damage
Eriksen, Anne Zebitz; Eliasen, Rasmus; Oswald, Julia; Kempen, Paul; Melander, Fredrik; Andresen,
Thomas Lars; Young, Michael; Baranov, Petr; Urquhart, Andrew
Published in:
A C S Nano
Link to article, DOI:
10.1021/acsnano.8b00596
Publication date:
2018
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Eriksen, A. Z., Eliasen, R., Oswald, J., Kempen, P. J., Melander, F., Andresen, T. L., ... Urquhart, A. J. (2018).
Multifarious Biologic Loaded Liposomes that Stimulate the Mammalian Target of Rapamycin Signaling Pathway
Show Retina Neuroprotection after Retina Damage. A C S Nano, 12(8), 7497-7508. DOI:
10.1021/acsnano.8b00596
Multifarious Biologic Loaded Liposomes that
Stimulate the Mammalian Target of
Rapamycin Signaling Pathway Show Retina
Neuroprotection after Retina Damage
Anne Z. Eriksen,† Rasmus Eliasen,† Julia Oswald,‡ Paul J. Kempen,† Fredrik Melander,†
Thomas L. Andresen,† Michael Young,‡ Petr Baranov,‡ and Andrew J. Urquhart*,†
†DTU Nanotech, Department of Micro- and Nanotechnology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
‡Schepens Eye Research Institute, Massachusetts Eye and Ear, 20 Staniford Street, Boston, Massachusetts 02114, United States
*S Supporting Information
ABSTRACT: A common event in optic neuropathies is the loss of axons and
death of retinal ganglion cells (RGCs) resulting in irreversible blindness.
Mammalian target of rapamycin (mTOR) signaling pathway agonists have
been shown to foster axon regeneration and RGC survival in animal models
of optic nerve damage. However, many challenges remain in developing ther-
apies that exploit cell growth and tissue remodeling including (i) activating/
inhibiting cell pathways synergistically, (ii) avoiding tumorigenesis, and
(iii) ensuring appropriate physiological tissue function. These challenges are
further exacerbated by the need to overcome ocular physiological barriers and
clearance mechanisms. Here we present liposomes loaded with multiple mTOR pathway stimulating biologics designed to
enhance neuroprotection after retina damage. Liposomes were loaded with ciliary neurotrophic factor, insulin-like growth
factor 1, a lipopeptide N-fragment osteopontin mimic, and lipopeptide phosphatase tension homologue inhibitors for
either the ATP domain or the c-terminal tail. In a mouse model of N-methyl-D-aspartic acid induced RGC death, a single
intravitreal administration of liposomes reduced both RGC death and loss of retina electrophysiological function. Fur-
thermore, combining liposomes with transplantation of induced pluripotent stem cell derived RGCs led to an improved
electrophysiological outcome in mice. The results presented here show that liposomes carrying multiple signaling
pathway modulators can facilitate neuroprotection and transplant electrophysiological outcome.
KEYWORDS: retina, liposomes, neuropathy, neuroprotection, ganglion, transplant
Optic neuropathies (e.g., glaucoma, etc.) are a leadingcause of irreversible blindness worldwide, impairingpatient quality of life and posing a negative impact on
socioeconomics.1 A common event in optic neuropathies is the
loss of RGC axons in both the optic nerve (ON) and retina,
followed by the death of RGCs.2,3 RGCs are responsible for
signal transmission from the retina to the brain and RGC death
through apoptosis4 is associated with progressive loss of vision.
Lack of regenerative capacity in the mammalian retina makes
the loss of RGCs irreversible. Autologous nerve grafts for ON
damage are undesirable due to excessive surgery (or unfeasible
depending on location of damage) while retina transplantation
for retina damage has had poor success.5 Multiple factors con-
tribute to neuronal loss in the retina including failure of axonal
transport; toxic pro-neurotrophins; intrinsic and extrinsic acti-
vation of apoptotic signals; mitochondrial dysfunction; exci-
totoxic damage; oxidative stress; misbehaving reactive glia;
loss of synaptic connectivity and neurotrophic factor (NF)
deprivation.6 The multifactorial nature of optic neuropathies
would indicate that a combination therapy (e.g., combined
pharmacotherapies, pharmacotherapy, and cell therapy, etc.)
linked to neuroprotection and/or nerve regeneration would
signiﬁcantly improve the outcome of optic neuropathies. This
is indicated by previous studies either involving the supple-
mentation of diﬀerent neurotrophic factors to protect RGCs
in diﬀerent animal models (induced hypertension, ON trans-
ection and ON crush7−13) or the deletion of cell growth
regulatory genes PTEN and SOCS3 to protect RGCs after
axotomy.14−16
Arguably, the most striking results in axon regrowth after
ON transection so far have been achieved by Bei et al. using a
combination of adeno-associated virus (AAV) assisted over-
expression of ciliary neurotrophic factor (CNTF), insulin-like
growth factor 1 (IGF-1) and osteopontin (OPN), combined
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with AAV codeletion of PTEN and SOCS3 genes.17 CNTF
and IGF-1 have both been shown to promote axon regener-
ation by activation of the mTOR pathway.4,17−20 The cytokine
CNTF is capable of activating several diﬀerent signaling
pathways such as JAK-signal transducers, MAPK, PI3K, and
mTOR-p70S6K by binding to receptors at the cell surface.21
CNTF has been shown to stimulate mTOR activation of
STAT3, hence implicating CNTF and mTOR as transcrip-
tional regulators in neuroblastoma cells.22 CNTF supplemen-
tation has also been shown to prevent the decrease in mTOR
activity in vitro in RGCs.23 IGF-1 is a protein hormone that
binds to a receptor tyrosine kinases (IGF-1R) on the cell sur-
face24 activating PI3K.25,26 IGF-1 and regulation of the MDM4/
2-p53-IGF-1 pathway has been shown to be critical for axonal
sprouting and neurological recovery after spinal cord injury.27
OPN is a secreted phosphoprotein that binds to receptors
recognizing the Arg−Gly−Asp protein motif.28 OPN is impli-
cated in maintenance and reconﬁguration of tissue integrity
during inﬂammation by modulating the extracellular matrix
(ECM).29 In a stroke model in Sprague−Dawley rat, OPN has
been shown to be neuroprotective,30 and in combination with
IGF-1, OPN has been shown to promote regeneration of alpha
RGCs after axotomy.31 Phosphatase tension homologue (PTEN)
is a phosphatase that dephosphorylates PIP3 to PIP2 resulting
in inhibition of the Akt/mTOR pathway. PTEN deletion by
virus mediated gene silencing has been shown to prevent RGC
apoptosis after ON cut32 and enhance the regenerative poten-
tial of neurons in the corticospinal tract.33
For clinical translation, combining mTOR pathway stimulat-
ing biologics for RGC neuroprotection requires modiﬁcations
that would provide better control over cell pathway modulator
(i.e., promoters, inhibitors, inducers, agonists and antagonists)
delivery, release, clearance and residency time. Nanocarriers
represent one of many possible solutions (e.g., microcarriers,
implants, etc.) in delivering multiple cell pathway modulators
while controlling modulator release. Nanocarriers protect sensitive
cargos from degradation, can reduce the eﬀect of clearance mech-
anisms and improve absorption of cargos across physiological
barriers. Liposomes, phospholipid vesicles frequently contain-
ing cholesterol, are an attractive delivery system for retina
diseases,34 oﬀering loading of both hydrophobic and hydro-
philic molecules, prolonged retention in the eye after intra-
ocular (intravitreal or subretinal) injection,35−39 protection
of cargo from degradation40 and have a history of clinical
approval.41 The majority of liposomal research in central ner-
vous system (CNS) aspects is associated with overcoming the
blood brain barrier to improve the delivery of drugs to the
brain.42−44 Liposomes and lipoplexes have been shown to
eﬀectively deliver the RPE65 gene, critical for vision, in RPE65
knockout blind mice leading to an improvement in vision.39
Limited work has been reported on neuroprotection and nerve
regeneration. Cationic liposomes and corresponding lipoplexes
have been used to transfer neurotrophic factor genes (e.g., glial
derived neurotrophic factor, nerve growth factor etc.) in both
spinal cord and brain injury models.45,46 These studies have
shown neuroprotection and partial restoration of locomotor
function.45,46 Immunomodulation, via the selective apoptosis
of monocytes and phagocytic macrophages using clodronate
loaded liposomes, has shown partial hindlimb recovery and
neuron repair in a rat spinal cord injury model.47 To our
knowledge, liposomes loaded with multiple cell pathway have
not previously been reported for CNS neuroprotection and
regeneration. Liposomes loaded with multiple cell pathway
modulators have the advantage of delivering theses modulators
to the cell microenvironment at the same time, facilitating a
synergistic eﬀect on single or multiple cell pathways. Further-
more, signaling pathway modulators are often highly eﬃca-
cious and only very low concentrations are required. This
reduces the need for high drug loading and maximizing the
space available to pack a range of therapeutic small molecules,
peptides and proteins into the liposome.
In this study, we present two liposome formulations that
promote neuroprotection through stimulating the mTOR path-
way. Liposome aqueous cores were loaded with CNTF and
IGF-1. Liposome membranes were loaded with lipid conjugated
peptides OPP and either PAP2 or PAP4. OPP is a peptide
analogue of the N-fragment of OPN (speciﬁcally the RGD and
α9β1/α4β1 domains
29) that has been shown to mimic the func-
tion of recombinant human OPN48 and lower cytosolic Ca2+ in
a way similar to OPN.49 PAPs are PTEN antagonist peptides
with PAP2 targeting the ATP B type domain and PAP4 tar-
geting the c-terminal tail of PTEN.50 We show that multi-
farious mTOR pathway stimulating biologic loaded liposomes
signiﬁcantly prevent RGC death and loss of retina electro-
physiological function in a N-methyl-D-aspartic acid (NMDA)
mouse model. To further explore combination therapy, we com-
bine one neuroprotective liposome formulation with induced
pluripotent stem cell (iPSC) derived RGC transplantation in
the NMDA mouse model and show improved electro-
physiological outcome of the transplantation.
RESULTS AND DISCUSSION
Liposomes. The palmitoyl (C16) conjugated peptides (i.e.,
lipopeptides) C16-OPP, C16-PAP2, and C16-PAP4 (referred to
as OPP, PAP2, and PAP4 from now on), were all successfully
synthesized and puriﬁed by semipreparative reverse phase
HPLC to a purity of >95% conﬁrmed by HPLC and MALDI-
TOF MS (Supplementary Figures S1 and S2). Liposomes were
produced as illustrated in Figure 1A. Liposomes showed low
polydispersity index (PDI < 0.1) with diameters close to 100 nm
in both DLS measurements (Figure 1B) and cryoTEM images
(Figure 1C). CryoTEM images showed spherical liposomes
that were predominantly unilamellar. All liposomes had a neg-
ative zeta potential, which is important for reducing cyto-
toxicity51,52 and in combination with surface PEGylation has
been shown to improve liposome diﬀusion throughout the
vitreous.53 Lip A and Lip B showed a slightly more negative
zeta potential than Lip C (−19 mv, −18 mv, and −13 mV,
respectively). The zeta potential of all the liposomes is similar
to previously reported values of unilamellar liposomes with
similar phospholipid compositions.54−56
The encapsulation eﬃcacy (EE%) normalized to the lipid
concentration was higher for Lip B than the EE% of Lip A, and
both formulations showed a higher EE% of CNTF (∼22 kDa)
than IGF-1 (7.7 kDa). These EE% approximately corresponded
to 700 nM IGF-1 and 763 nM CNTF concentrations for Lip A,
while for Lip B the concentrations were 1.53 μM IGF-1 and
1.27 μM CNTF. These values indicate that IGF-1 and CNTF
both loaded in approximately a 1:1 ratio in both formulations
and that macromolecule size did not inﬂuence loading. These
concentrations were well above the IC50 values of IGF-1 and
CNTF (i.e., < 6 nM),57,58 while keeping the injected concen-
tration of CNTF low enough to not induce suppression of
retina electrophysiological function.59
The diﬀerence in EE% between the two formulations is
likely to be due to the diﬀerent PTEN inhibitor lipopeptides
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incorporated into the membrane. PAP2 has a cysteine with a
free thiol group that can react with other thiol groups, either
from other PAP2 lipopeptides in a liposome bilayer or on
proteins (e.g., present in FBS, IGF-1, etc.), possibly reducing
protein loading or increasing liposome leakiness during puriﬁ-
cation. This is supported by the observation that neither Lip A
or Lip B leaked calcein (a small hydrophilic ﬂuorescent dye) at
37 °C in HBS. However, Lip A did leak calcein over time when
10% FBS was added to HBS at 37 °C (Supplementary Figure S3),
indicating an interaction that resulted in liposome bilayer insta-
bility. The low EE% ensured that the proteins were fully
hydrated and did not aggregate inside the liposomes. This is
supported by the absence of visible internal structures in the
cryoTEM images in Figure 1C. The bioactivity of Lip A and
Lip B was tested in vitro in HEK293T cells (Supplementary
Figure S4). Phosphorylation of Akt and p70S6K was observed
for both formulations, indicating that the cargos remained
biologically active.
Liposome Uptake in Retinal Organoids. The cellular
uptake of liposomes was tested in vitro in retinal cell organo-
ids diﬀerentiated from mouse embryonic stem (mES) cells
(Figure 2A).60 This system has advantages over traditional 2D
cultures, including more relevant pharmacokinetic results.61−63
Retinal organoids were cultured for 21 days and then exposed
to liposomes labeled with Atto655 for 12 h. The level and cell
speciﬁcity of uptake was quantiﬁed by ﬂow cytometry
(Supplementary Figure S5). The overall uptake of liposomes
(Figure 2A) showed that Lip B had the lowest uptake with
approximately 13% of cells showing uptake. The control lipo-
some, Lip C, showed a slightly higher cellular uptake (18% of
cells) than Lip B. The highest uptake was observed for Lip A
with 23% of cells showing uptake. The variance between
replicas of Lip A was signiﬁcantly larger than that of either Lip
B or Lip C. Statistical analysis between the liposome formula-
tions was carried out, and none of the formulations showed
signiﬁcantly diﬀerent uptake compared to Lip C. However, Lip
A had a signiﬁcantly higher uptake than Lip B. The higher
uptake observed for Lip A might be explained by sulfur−sulfur
interactions between the cysteine in PAP2 and thiol groups on
the cell surface. Cell surface thiols interacting with thiols
present on nanomaterials has been argued as a mechanism to
enhance uptake into cells.64
Retinal organoids were approximately 1 mm in diameter
(Figure 2A). Retinal cells are between 9 and 12 μm in diameter65
and assuming organoids are densely packed perfect spheres then
approximately 1% of the cells are located on the organoid surface,
indicating that the liposomes were capable of moving (i.e., by
active transport and/or passive diﬀusion) beyond the surface
layer of cells. It has previously been reported that nanocarriers
can penetrate beyond the surface layer of cells in 3D cell aggre-
gates.66−68 To determine if liposome uptake was associated
with speciﬁc cell types, organoids were dissociated and stained
for ﬁve major retinal cell type markers. The markers used were
antirecoverin-Rb-IgG (Chemicon) for photoreceptor cells,
Figure 1. Liposome characterization: (A) Schematic drawing of liposomes with encapsulated IGF-1, CNTF, lipopeptide OPP, and
lipopeptide PTEN inhibitors (PAP2 or PAP4); (B) liposome size, polydispersity index (PDI), zeta potential, and protein encapsulation
eﬃciency. Liposome diameter and PDI were measured by DLS in HBS, zeta potential was measured in 10 mM HEPES with 5% glucose.
Encapsulation eﬃciency (EE%) of spin-ﬁlter puriﬁed liposomes was assessed by ELISA (N = 3); (C) CryoTEM images of liposome
formulations (scale bar = 100 nm).
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anti-PKC-α-m-IgG (Santa Cruz) for bipolar cells, anti-RBPMS-
Rb-IgG (Abcam) for RGCs, anticalbindin-Rb-IgG (Sigma-
Aldrich) for horizontal cells and antiglutamine synthetase-Rb-
IgG (GS) (Abcam) for Müller glia cells.69,70 No diﬀerence in
uptake between the diﬀerent cell types was observed (see
Figure 2B) but it should be noted that retinal cells are not fully
mature at day 21.
In Vivo Preservation of Retinal Function by Loaded
Liposomes. RGC death was induced in the right eye of
C57BL/6J mice by a single intravitreal injection of N-methyl-
D-aspartic acid (NMDA, 2 μL at 20 mM). Mice were divided
into three treatment groups receiving 1 intravitreal injection of
either Lip A, Lip B, or Lip C liposomes 2 h after the NMDA
injection. Four weeks after the liposome treatment the retinal func-
tion of dark-adapted mice were evaluated by electroretinography
(ERG) and eyes were enucleated for histological analysis
(Supplementary Figure S6). NMDA treated mice receiving
empty liposomes (Lip C) were used as controls. NMDA binds
irreversibly to the NMDA receptor at the postsynaptic mem-
brane leading to an excessive inﬂux of positive ions (e.g., Ca2+),
depolarizing the mitochondrial membrane and ultimately trig-
gering apoptosis.71−73 NMDA has shown retinal toxicity at low
concentrations (e.g., 20 nM) with the degree of inner retina
damage corresponding to NMDA concentration.74 NMDA
aﬀects other retina cell types and intravitreal administered
NMDA also induces partial optic nerve damage, likely linked
to the damage of the inner retina. A 20 mM NMDA injection
is an extreme model of retina damage. We observed no
signiﬁcant diﬀerence in a-wave response (Figure 3A), asso-
ciated with photoreceptors, between healthy control eyes and
NMDA-injected eyes. This conﬁrmed that intravitreal NMDA
injection at 20 mM concentration did not result in photoreceptor
damage, which is consistent with previous observations.74,75
The b-wave response, associated with the function of inter-
neuron cells (e.g., amacrine and horizontal) and bipolar neuron
cells,72,76,77 showed a signiﬁcant decrease in all NMDA-injected
groups (Figure 3B) compared to healthy controls. At low con-
centrations (<50 nM) NMDA has been shown to damage
amacrine cells but bipolar cell damage has only been reported
for higher concentrations (>200 nM).78 At 20 mM NMDA con-
centrations, substantial bipolar and interneuron cell damage
will have occurred. We observed a signiﬁcant protective eﬀect
of Lip A compared to the empty liposome Lip C (P value <
0.02). Lip B showed no signiﬁcant diﬀerence in b-wave
response compared to either the Lip A or Lip C treated groups.
The Lip B treated group did show a trend which indicated a
minor preservation of b-wave response than the Lip C treated
group. A-wave and b-wave amplitudes in healthy eyes between
C57BL/6J mice were similar to previous reports.79
Scotopic threshold response (STR, Figure 3C) has been related
to the function of the inner retinal neurons more proximal than
the bipolar cells (e.g., RGCs).2,75,80,81 To estimate the neuro-
protective eﬀect, the diﬀerence in STR amplitudes (pSTR −
nSTR) between the healthy (left) and treated (right) eye for
each animal was determined (i.e., ΔSTROS‑OD, Figure 3C).
A lower ΔSTROS‑OD therefore means a return of function and
Figure 3. Electroretinogram amplitude values from dark-adapted mice. (A) A-wave response for healthy and treated eyes. Box plot median
values are −15.6 μV for healthy eye, −9.9 μV for Lip A, −15.5 μV for Lip B, and −29.1 μV for Lip C. (B) B-wave response for healthy and
treated eyes (*P ≤ 0.05 between Lip A and Lip C). Box plot median values are 214.3 μV for healthy eye, 138.7 μV for Lip A, 104.7 μV for Lip
B, and 83.5 μV for Lip C. (C) The change in scotopic threshold response, ΔSTR (pSTR − nSTR), between the healthy left (oculus sinister,
OS) and liposome treated damaged right (oculus dexter, OD) eyes. Box plot median values are 27.6 μV for Lip A, 7.4 μV for Lip B, and
32.2 μV for Lip C. Highly negative values (greater than −10 μV) were excluded from ΔSTR assuming natural visual impairment in the
healthy control eye. N = 8−10 mice per liposome treated group, N = 28 mice for healthy control eye.
Figure 2. Liposome uptake in retinal organoids. (A) Box and whiskers plot of the total liposome uptake (as % positive cells for Atto655) in
retinal organoids (*P ≤ 0.05 between Lip A and Lip B, N = 4). Inset shows an example micrograph of a retinal organoid cultured to day 21
(scale bar, 1 mm). The box plot median values are 22.6%, 12.8%, and 18.4% for Lip A, Lip B, and Lip C, respectively. (B) Liposome uptake
(as % positive cells for Atto655) in speciﬁc cell types found in retinal organoids using cell markers. The cell types shown are photoreceptors
(recoverin), bipolar cells (PKC-α), RGCs (RBPMS), horizontal cells (calbindin), and Müller glia cells (glutamine synthetase (GS)). Error
bars show standard error of the mean (****P ≤ 0.0001 between Lip A and Lip B, no signiﬁcant diﬀerence between cell types, N = 4).
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an inner retinal neuronal response closer to the healthy eye,
with full restoration giving a ΔSTROS‑OD = 0. For ΔSTROS‑OD,
no signiﬁcant diﬀerence was found between the treatment
groups (ANOVA p > 0.05). However, both Lip A and Lip B
treated groups showed clear trends toward better preservation
of STR. For Lip A the spread of data points is divided into two
groups suggesting a bimodal distribution (responsive and unres-
ponsive), in which the responsive group has a ΔSTROS‑OD of
∼7 μV. The Lip B treated group showed a more unimodal
distribution with more than 75% of the mice around the
median ΔSTROS‑OD of 7.4 μV (the median for Lip C treated
group is 32.2 μV for comparison).
Extrapolation of the ERG data would indicate that Lip A had
a signiﬁcant protective eﬀect on interneuron and bipolar neu-
ron cells but a mixed eﬀect on RGCs. Conversely, Lip B showed
no signiﬁcant protective eﬀect on interneuron and bipolar cells
but indicated a protective eﬀect on RGCs. The reasons for this
observation are likely manifold. PTEN inhibition may be a
critical factor and peptides that inhibit regions of PTEN might
induce diﬀerent responses in diﬀerent cell types. Equally, the
concentrations of IGF-1 and CNTF needed for protection
combined with appropriate release kinetics might be speciﬁc to
speciﬁc cell types. Interestingly, NMDA activation of the p38
MAPK pathway has been shown to be pro-apoptotic for RGCs
and pro-survival for photoreceptors.82 Given IGF-1 and CNTF
will promote a number of signaling pathways (e.g., MAPK for
IGF-1) and that signaling pathway dynamics are likely diﬀerent
between speciﬁc cell types, loading multiple pathway regulators
into liposomes may lead to speciﬁc eﬀects (positive and neg-
ative) on speciﬁc cell types rather than promote positive eﬀects
in tissue as a whole.
In Vivo Rescue of RGCs by Loaded Liposomes.
To evaluate the eﬀect of a single intravitreal injection of Lip
A and Lip B on host RGC survival after NMDA induced RGC
death, retinal whole mounts were stained for RBPMS and imaged
on a confocal microscope. Three images per retina were acquired,
approximately 1 mm away from the optic nerve head. Example
micrographs from a healthy control eye, an eye threated with
Lip A, and an eye treated with Lip C are shown in Figure 4
panels A, B, and C, respectively. RGCs in each image were
counted and the average number of surviving RGCs in the
three images was calculated to enable quantitative comparison
between the groups (Figure 4D). NMDA injection in combina-
tion with Lip C resulted in substantial RGC loss (∼75% loss
compared to the healthy controls). This observation is consistent
with previous quantiﬁcations of RGC loss in mice without
empty liposomes.83 This result showed that Lip C did not have
a neuroprotective eﬀect. Treatment with either Lip A or Lip B
was not able to completely prevent RGC loss.
Statistical analysis showed a signiﬁcant diﬀerence between
Lip A and Lip C treated groups but no diﬀerence between Lip
B and Lip C treated groups (552 cells/mm2, 379 cells/mm2
and 360 cells/mm2 median values for Lip A, Lip B and Lip C
respectively). The RGC rescue data indicated that although
Lip B showed a trend to preserve the electrophysiological func-
tion associated with RGCs, this did not translate into a greater
number of rescued RGCs. Lip A treated mice showed the
greatest variance in surviving RGCs and also showed a bimodal
trend in STR. This indicates that a number of mice within the
group responded very well to the treatment with Lip A, prob-
ably due to a range of reasons. There is a lack of knowledge in
the supportive role, if any, of amacrine and bipolar cells on
RGC survival. Given Lip A improved b-wave response
(associated with amacrine and bipolar cells) and showed the
greatest number of surviving RGCs it would indicate that
amacrine and bipolar cells support RGC survival. However, the
STR for Lip A treated mice indicates that although there are
more RGCs present than in Lip B treated mice, the function of
these RGCs has been compromised.
Loaded Liposomes in Combination with Transplant
RGCs Improve ΔSTROS‑OD. We investigated the eﬀect of the
liposomes in combination with RGC transplantation. NMDA
and liposome injections were performed as described above.
Transplant RGCs (tRGCs), diﬀerentiated from Thy1-GFP
induced pluripotent cells (iPSC)84 were transplanted by intra-
vitreal injection 4 days after NMDA injection. Retina progenitor
cells and neuroretinal cells have both been proposed as cell
therapies and cell transplants into both young animals and
ex vivo retinas have shown some success.85,86 However, good
integration and survival of transplant cells in adults remain a
challenge.87 The combinatorial eﬀect of liposomes and RGC
transplantation was evaluated by retina electrophysiological
function and donor cell survival 4 weeks after the transplant-
ation (Figures 5 and 6). We chose Lip A as the liposome for-
mulation due to improved RGC survival, better b-wave response,
and the indication that STR was preserved in approximately 50%
of mice.
No diﬀerence in a-wave response was observed between the
healthy eyes and the treated eyes (Figure 5A). The b-wave
response showed a signiﬁcant diﬀerence between the treated
groups and healthy control as well as between the two treated
Figure 4. RGC rescue by liposomes after NMDA induced damage
of mouse retinas. Example retina micrographs from (A) a healthy
control eye; (B) a Lip A treated eye, and (C) a Lip C treated eye.
In all micrographs RGCs nuclei were labeled with RBPMS
Alexa647 (red), white scale bars are 60 μm. (D) Box and whiskers
plot showing the density of surviving RGCs in healthy and
liposome treated damaged eyes (*P ≤ 0.05 between Lip A and
Lip C). Each dot shows an average RGC density for an eye,
calculated from three micrographs taken 1 mm away from the optic
nerve head. The box plot median values are 1728 RGCs/mm2 for the
healthy eye, 553 RGCs/mm2 for Lip A, 380 RGCs/mm2 for Lip B,
and 360 RGCs/mm2 for Lip C. N = 6−8 mice per group.
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groups (Figure 5B). There was no signiﬁcant diﬀerence in
b-wave response between Lip A treated and Lip A in com-
bination with tRGCs treated mice. This result indicated that
the transplant RGCs (tRGCs) did not contribute to the b-wave
response and that Lip A alone had a protective eﬀect. This is
corroborated with the b-wave response for tRGCs combined
with Lip C, which resulted in similar b-wave amplitudes to
empty liposomes (i.e., Lip C) alone. The ΔSTROS‑OD data
(Figure 5C) showed that a combination of Lip A and tRGCs
resulted in a signiﬁcant rescue of RGC associated electro-
physiological function (median = 3.3 μV) compared to Lip A
treatment alone (median = 27.6 μV). Lip C in combination
with tRGCs showed no rescue of STR, while Lip A in com-
bination with tRGCs resulted in a signiﬁcant improvement in
ΔSTROS‑OD compared to all other treatments. The ERG data
does indicate that the loaded liposomes (Lip A) support tRGCs
in a manner that improved host STR. The observation that
empty liposomes (Lip C) in combination with tRGCs showed
no rescue of STR supports this argument. Interestingly, Lip A
in combination with tRGCs signiﬁcantly reduced ΔSTROS‑OD
variance and eliminated the bimodal distribution seen in Lip A
alone. These results indicate that both activation of cell growth
signal pathways and the protection of other retina cell types
(e.g., amacrine, bipolar, etc.) may be critical to transplant RGCs
restoring host tissue function.
The eﬀect of the combined treatment on host RGCs survival
was evaluated by RBPMS staining and confocal microscopy
(Figure 6). The host RGC density of the healthy control eyes
and the treated eyes are shown in Figure 6A. We were not able
to identify a signiﬁcant additive eﬀect of tRGCs on host RGC
survival (552 cells/mm2 for Lip A and 527 cells/mm2 for Lip A +
tRGCs). This indicated that it was Lip A alone that promoted
host RGC survival. Next, we investigated the eﬀect of the
liposomes on the survival of tRGCs. Retinal whole mounts
were double-stained for GFP (marker for tRGCs) and RBPMS
(host and transplant RGCs). Host RGCs expressed RBPMS at
higher levels than the tRGCs resulting in limited colocalization
of red and green ﬂuorescence for the tRGCs. It is worth
emphasizing that the low RBPMS expression in tRGCs is likely
due to the tRGCs not yet being fully mature (Supplementary
Figure S7). tRGC survival was observed in both Lip A and Lip
C groups (Figure 6 and Supplementary Figure S8) 4 weeks
after transplantation, showing a longer survival time for tRGCs
compared to previous reports on transplanted cells.88−90
Axon sprouting was observed in both Lip A and Lip C
groups when combined with tRGCs (Figure 6C). Surviving
tRGC numbers after 1 month were very low and no signiﬁcant
diﬀerence in survival of the transplanted cells was observed
between Lip A and Lip C groups. Transplant cell survival is a
major challenge in cell transplantation.87 Additionally, the
NMDA induced apoptotic environment in the host eye will
Figure 5. Electroretinogram amplitude values from dark-adapted mice undergoing treatment with liposomes and transplant RGCs (tRGCs).
(A) A-wave response for healthy and treated eyes. (B) B-wave response for healthy and treated eyes (*P ≤ 0.05 between Lip A + tRGCs and
Lip C + tRGCs. *P ≤ 0.05 between Lip A and Lip C). (C) ΔSTROS‑OD for liposome treated and liposome plus tRGC treated damaged eyes
compared to healthy controls. Highly negative values (greater than −10 μV) were excluded from the ΔSTR assuming natural visual
impairment in the control eye. One outlier was identiﬁed in the Lip A + tRGCs group and excluded from the statistical analysis (*P ≤ 0.05
between Lip A and Lip A + tRGCs. *P ≤ 0.05 between Lip A and Lip C + tRGCs. **P ≤ 0.01 between Lip A + tRGCs and Lip C + tRGCs).
N = 8−10 mice per treated group, N = 17−44 mice for healthy control (panels A and B). N = 7−9 mice per treated group (panel C).
Figure 6. Host and transplant RGC survival. (A) Box and whiskers
plot showing host RGC density in healthy eyes (median =
1728 cells/mm2) and NMDA damaged host eyes (median values for
Lip A + tRGCs = 528 RGCs/mm2, Lip C = 360 RGCs/mm2, and Lip
C + tRGCs = 415 RGCs/mm2) 4 weeks after NMDA injection (*P ≤
0.05 between Lip A and Lip C). (B) Box and whiskers plot of tRGC
survival in combination with liposomes (median values of 219 and
409 for Lip A and Lip C, respectively). (C) Example micrographs
from the Lip A + tRGCs group. Transplant RGCs are in green, host
RGCs in red (white arrows indicate axons, scale bar = 60 μm). The
insert ﬁgure shows an example tRGC with axon (scale bar = 60 μm).
(D) Example whole retina tile scan from the Lip A + tRGCs group
used for cell counting. In all microscopy images tRGCs are in green
(GFP) and host RGCs are in red (RBPMS). White circles highlight
example areas containing tRGCs (scale bar = 1 mm, see
Supplementary Figure S9 for larger image). N = 6−8 mice per
group (panels A and B).
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have also induced tRGC apoptosis as NMDA induced toxic
eﬀects to retina cells has been shown to have a prolonged
duration (up to 14 days).74 The nonspeciﬁc (i.e., not asso-
ciated with intact cells) green ﬂuorescence observed in the
whole retina tile scans is likely GFP debris from the tRGCs
combined with tissue autoﬂuorescence (Figure 6D). Trans-
plant cell survival has been shown to be improved by injury
and loss of host RGCs.91 The rescue of host RGCs by Lip A
may explain the lack of an observed eﬀect of Lip A on tRGC
survival. Another possible explanation could be linked to the
timing and concentration of the delivered mTOR pathway
promoters. Delivery of growth factors at appropriate concen-
trations is important for RGC survival in the neonatal retina
and likely to be critically important in inducing a signiﬁcant
positive eﬀect on the survival of transplanted cells.
CONCLUSION
Liposomes loaded with multiple mTOR pathway stimulating
biologics showed a signiﬁcant improvement in retina electro-
physiological function after a single injection in an NMDA mouse
model with extensive retina damage. Multifarious mTOR path-
way stimulating biologic loaded liposomes improved b-wave
response and STR. These liposomes also improved host RGC
survival after NMDA exposure. Liposomes in combination with
tRGCs showed a signiﬁcant improvement in STR compared to
liposomes alone. This indicated that liposomes improved the
electrophysiological outcome of the transplantation. The results
show that multifarious mTOR pathway stimulating biologic
loaded liposomes can facilitate both neuroprotection across a
number of speciﬁc cell types and RGC transplantation. Further
research, particularly in dosing dynamics (e.g., modulator
concentrations, modulator combinations, number of injections,
time between injections, etc.), is required to develop clinically
viable neuroprotective and transplant facilitating nanomedi-
cines.
METHODS
Lipopeptide Synthesis. All peptides were synthesized using a
Biotage Initiator Alstra peptide synthesizer (Biotage) on a TentaGel S
RAM resin (Sigma-Aldrich) at the 0.5 mmol scale using established
solid phase methods (Supplementary Figure S1).92 All chemicals (e.g.,
amino acids, solvents, coupling agents, etc.) were purchased from
Sigma-Aldrich or Bachem. Brieﬂy, couplings were 5 min at 75 °C
using 4 equiv amino acid, 3.92 equiv O-(7-azabenzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexaﬂuorophosphate (HATU), and 8 equiv
2,4,6-collidine in DMF. Fmoc deprotection was done using 20%
piperidine in DMF. Peptides were conjugated to palmitic acid (C16) at
the N-terminus using established HATU/collidine coupling chemistry
(1:2:4 molar ratio for palmitic acid/HATU/collidine) to form
lipopetides and cleaved from the support using triﬂuoroacetic acid,
water, and triisopropylsilane (95:2.5:2.5). In the case of PAP2 cleav-
age was performed using triﬂuoroacetic acid, water, triisopropylsilane
and ethanedithiol (92.5:2.5:2.5:2.5).
Lipopeptides were precipitated in cold diethyl ether and ﬁltered oﬀ.
Crude lipopeptide was dissolved in a acetonitrile:water (1:1) solution
and puriﬁed using preparatory HPLC (Waters) on a C18 column
(Xterra). A water (5% acetonitrile, 1% triﬂuoroacetic acid) acetonitrile
(0.1% triﬂuoroacetic acid) gradient was used starting at 10% acetonitrile
and increasing to 60% acetonitrile over 25 min. All lipopeptides had a
purity ≥95%. Lipopeptide molecular weight was conﬁrmed using a
autoﬂex MALDI-ToF MS (DHB, 0.1% TFA matrix, Bruker) and
purity by analytical HPLC (C8 column, Gilson). The lipopeptides had
the following sequences: (OPP) C16-PTVDVPDGRGDSLAYGLRSK;
(PAP2) C16-KHKNHYKIYNLCAE; and (PAP4) C16-TVEEPSNPEAS-
SSTSVTPD. Lipopeptide HPLC chromatograms and MALDI-ToF
MS spectra can be found in the Supporting Information (Supplementary
Figure S2).
Preparation of Liposomes and Loading of Proteins. All lipids
were purchased from Avanti Polar Lipids and had a purity of ≥98%.
Liposomes were prepared by dissolving pure lipids in 9:1 tertiary
butanol/water and then pipetting them together to give the relevant
lipid mixtures. The lipid mixtures were then lyophilized to dry lipid
powders overnight using freeze-drying. The lipid powders were
subsequently hydrated over 1 h by adding 10 mM HEPES buﬀered
saline pH = 7.4 (HBS) at 60 °C and shaking every 10 min. The
liposomes were extruded through a 100 nm pore size ﬁlter 21 times at
60 °C and stored at 4 °C until use. Liposomes were composed of 1,2-
dipalmetoyl-sn-glycerol-3-phosphatidylcoline (DPPC), cholesterol
(Chol), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-
(polyethylene glycol)-2000] ammonium salt (DPPE-PEG2000), OPP,
and PAP2 or PAP4. Liposome A (Lip A) comprised DPPC/Chol/
DPPE-PEG2000/OPP and PAP2 in a 53:40:5:1:1 mol % ratio.
In liposome B (Lip B), PAP2 was replaced with PAP4 at the same
mol %, all other lipid percentages were the same. A control liposome
(Lip C) without any proteins or lipopeptides had a composition of
DPPC/Chol/DPPE-PEG2000 (55:40:5 mol %).
The proteins were loaded into preformed liposomes following
established methods.93 Brieﬂy, CNTF and IGF-1 (recombinant human
CNTF and recombinant human IGF-1, Cell Guidance Systems) were
dissolved in HBS at 0.25 mg/mL and mixed with liposomes. The
mixture was snap frozen in liquid N2 and thawed in a water bath at
37 °C, this process was repeated once. Nonencapsulated proteins
were removed by spin-ﬁltration with a 100 kDa spin ﬁlter (Merck),
using HBS as eluent. The concentration of encapsulated protein was
determined by ELISA (R&D Systems) following the instructions of
the manufacturer. Lipid concentrations were detected by ICP-MS
(Thermo Scientiﬁc). Encapsulation eﬃciency (EE%) of the CNTF
and IGF-1 was determined by normalizing the protein concentration
before and after puriﬁcation to the actual lipid concentration, as
described in eq 1.
= [ ] [ ]
[ ] [ ]
EE%
protein / lipid
protein / lipid
100end end
start start (1)
.Normalizing protein concentration to lipid concentration, rather than
describing EE% as a change in protein concentration only, takes into
account changes in volume from puriﬁcation steps.
Liposome Characterization by DLS and Zeta-Potential.
Liposome hydrodynamic diameter and zeta-potential were measured
on a Brookhaven ZetaPALS. For size measurements liposomes were
diluted in HBS. Zeta-potential was measured on liposomes diluted in
10 mM HEPES, 5% glucose at pH 7.4.
In Vitro Liposome Stability. Liposome stability was evaluated at
4 °C by following changes in size and polydispersity index (PDI) of
loaded liposomes over time. Sizes and PDI were measured by DLS as
described above. The ability of the liposomes to retain the loaded
content was assessed by encapsulation of a self-quenching concentra-
tion (20 mM) of the hydrophilic ﬂuorophore, calcein (Sigma-Aldrich).
Liposomes were formulated as described above, adding 20 mM calcein
in HBS for hydration of the lipid powder. Nonencapsulated calcein
was removed by size exclusion chromatography (SEC) on a Sephadex
G50 column using HBS. The calcein loaded liposomes were then split
into diﬀerent vials, kept at 4 or 37 °C. A 100 μL aliquot of each
sample at a concentration of 0.1 mM was subsequently transferred to
a black ﬂat bottom 96 well plate, and the ﬂuorescent signal was
measured in a plate reader (Wallac Victor3 1420 Multilabel Counter)
before and after lysing the liposomes with 2 μL of 10% Triton X
(Sigma-Aldrich). The ratio of the ﬂuorescent signal of lysed liposomes
over intact liposomes was then plotted against time to generate a
leakage proﬁle.
Bioactivity assay of liposomes by Western Bolt. To test the
ability of Lip A and Lip B to inﬂuence the mTOR/Akt pathway,
HEK293T (Sigma-Aldrich) cultured in Dulbecco’s modiﬁed eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS)
(Sigma) and 5% penicillin−streptomycin in a six well plate was
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incubated for 12 h with 0.4 mM liposomes at 37 °C 5% CO2. Cells
incubated with Lip C were used as a control. Semiquantitative analysis
for Akt activation was performed by Western blot (WB) following
standard protocol. In brief, cells were washed with cold PBS and
collected by mechanical scraping in 200 μL of cold PBS, with phos-
phatase inhibitor cocktail 2 (Sigma-Aldrich) and complete Mini EDTA
free protease inhibitor cocktail (Roche). Cells were transferred to
clean 1.5 mL tubes kept on ice. The cells were lysed by adding 200 μL
of hot (∼96 °C) 4× protein loading buﬀer (Li-Cor) with 10%
mercaptoethanol (Sigma-Aldrich), and the mixture was boiled for
5 min before loading 15 μL of the whole cell lysate in a 1.5 mm Nu
PAGE 4−12% Bis-Tris Gel (Invitrogen). Five microliters of chameleon
700 prestained protein ladder (Li-Cor) was loaded in the outermost
wells. Electrophoresis was run at 100 V in Nu PAGE running buﬀer
(Invitrogen) for 2 h.
The proteins were transferred to a nitrocellulose membrane
(Invitrogen) in 25 mM Tris, 190 mM glycine, and 20% methanol
buﬀer at pH 8.3. The nitrocellulose membrane was blocked with
odyssey blocking buﬀer for 1 h at room temperature, washed with Tris
buﬀered saline (Sigma-Aldrich) 0.1% Tween 20 (Sigma-Aldrich)
(TBST), and stained with anti-Akt1-Rb-IgG (abcam) overnight at
4 °C. The membrane was washed with TBST and incubated for 1 h
with secondary stain Gt-anti-Rabbit IgG DyLight 800 (Invitrogen)
before imaging the membrane on an Odyssey FC imaging system (Li-
Cor). The antibody was then stripped using Revitablot Western blot
stripping buﬀer (Rockland) before reblocking, and staining overnight
with anti-Akt1/2/3-Rb-IgG (Abcam) at 4 °C. Akt1/2/3 was labeled
with IRDye 680RD Gt-anti-Rb (Li-Cor) and imaged. The same
methodology was used for p70S6 kinase, except anti-p70S6K-Rb-IgG
(Invitrogen), and anti-Phospho-p70S6K (Thr421, Ser424)-Rb-IgG
(Invitrogen) were used. Densitometry was made by drawing rectangles
over appropriate bands, obtaining the intensity, and dividing the
intensity by the control (e.g., Akt1/2/3 or p70S6K).
Culture of Retinal Organoids. Murine embryonic stem cells
(mESCs) were thawed and seeded in T75 ﬂasks precoated with 1%
Matrigel in DMEM for 20 min. Cells were cultured in ESC mainte-
nance medium (ES medium, see Supporting Information for all media
components), at 37 °C, 5% O2, 5% CO2, until 80% conﬂuency. Cells
were then collected by trypsinization and seeded in 96 tissue culture
plates (Falcon Corning) at 20 000 cells/well in optic vesicle media
(OV-medium) (Day 1). After seeding on day 2, 1% Matrigel in 50 μL
of OV medium was added to each well. At day 5, 100 μL of 0.5%
Matrigel in OV medium was added. Day 9, 100 μL of media
from each well was replaced with 100 μL of optic cup medium
(OC-medium) without disturbing the cell aggregate. The retinal
organoids were maintained by replacing 100 μL of medium per well
with fresh OC-medium every third day until the optic cups were used
at Day 21 after seeding.
Liposome Uptake in Retinal Organoids. For in vitro uptake
studies, liposomes with the same membrane composition as Lip A,
Lip B, and Lip C were prepared adding 0.5 mol % of the ﬂuorescently
labeled lipid (DPPE-Atto655). Optic cups at Day 21, were pooled 6
to a well and ∼100 optic cups per formulation were incubated with
400 μM liposomes in OC-medium for 12 h. The 100 aggregates were
then collected in a Falcon tube and washed twice with 10 mL of
Hanks buﬀered saline solution (HBSS). Cells were dissociated by
adding 10 mL of Trypsin-EDTA 1X (T = 37 °C). Optic cups were
mechanically disturbed by pipetting and vortexing periodically, during
the 5 min trypsin incubation in a 37 °C heat bath. The trypsin was
inhibited by adding an equivalent volume of medium. Cells were then
pelleted and resuspended in 500 μL of HBSS before passing through a
cell strainer. Cells were ﬁxed by incubation for 30 min on ice in
1.5 mL of 4% paraformaldehyde (Sigma-Aldrich). Cells were washed
with 12 mL of PBS and resuspended in 3 mL of blocking buﬀer;
0.05% Digitonin (5% in water, Invitrogen), 10% goat serum, 0.1%
sodium citrate, 1% bovine serum albumin (BSA) in PBS, for 30 min at
room temperature. Cells were washed twice with 12 mL of PBS and
the pellet was resuspended in appropriate volume of staining buﬀer.
Cells were then divided into a 350 μL microwell plate and incubated
with an appropriate amount of primary antibody overnight at 4 °C.
Cells were washed three times with PBS and incubated with secondary
antibody, (antimouse-Alexa488 or antirabit-Alexa488 (Jackson Immu-
noResearch)) for 1 h at room temperature. Cells were washed three
times with PBS and resuspended in 250 μL of PBS. Cell uptake was
evaluated by ﬂow cytometer on a BD LSR II (BD Bioscience), collecting
data in the APC-A and FITC channel, analyzing 10.000 events per
sample.
In Vivo Eﬃcacy of Liposomes and Progenitor Cell Trans-
plants. All animal experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) at Schepens Eye Research
Institute. C57BL/6J (Charles River Laboratories) mice were kept
on a 12 h light 12 h dark cycle. Food and water were provided ad
libitum. Mice were anesthetized by intraperitoneal (IP) injection of
100−200 mg/kg ketamine and 20 mg/kg xylazine (Accutome). Under
anesthesia the mice were given one eye drop of tropicamide and one
intravitreal injection of 2 μL of 20 mM N-methyl-D-aspartic acid
(NMDA) in the right eye, using a 100 μm diameter glass pipet.94−96
Care was taken not to injure the lens during the procedure. The left
eye was kept as contralateral control. After the procedure GenTeal
was applied to both eyes. Two h after injection of NMDA, mice
were anesthetized by isoﬂuorane inhalation using O2 as the carrier gas.
Mice were then given one 2 μL intravitreal injection of 10 mM
liposome suspension of either Lip A, Lip B, or empty Lip C, into the
right eye. GenTeal was applied to the injected eye. Four days after
NMDA injection, three groups were anesthetized by IP injection of
100−200 mg/kg ketamine and 20 mg/kg xylazine and transplanted
with 20 000 GFP+ transplant RGCs by intravitreal injection of 2 μL of
cell suspension in PBS. Four weeks after transplantation ERGs were
recorded, mice were euthanized, and eyes were collected.
GFP Expressing RGCs for Transplantations. RGC diﬀer-
entiation, isolation, and selection were performed as described
before.84 Brieﬂy, murine Thy1-GFP iPSCs, kindly provided by the
laboratory of Joshua Sanes, were diﬀerentiated into retinal tissue in
three-dimensional retinal organoids through 21 days culture following
the retinal organoid protocol described above. At day 21 aggregates
were collected washed with HBSS and dissociated with freshly
activated papain in 1.1 mM EDTA, 0.3 mM β-mercaptoethanol,
5.5 mM cysteine-HCl in 50 mL of HBSS preincubated for 30 min at
37 °C, 5% CO2, 5 mL per 500 aggregates. Aggregates were left in
active papain for 3 min, vortexing thoroughly to mechanically disso-
ciate the cells. The cell suspension was then mixed 1:1 with DTI−
benzonase and passed through a 40 μm cell strainer. The strainer was
washed with an equal volume of DTI−benzonase, and cells were spun
down and resuspended in RGC medium (see Supporting Information).
GFP+ RGCs were isolated using magnetic beads (Dynabeads,
Invitrogen) with anti-Thy1, following the instructions of the manufac-
turer. Cells were counted using Trypan-blue staining, suspended in
HBSS.
Electroretinography. The function of retinal ganglion cells was
assessed by electroretinography (ERG)-scotopic threshold response
(STR) using a Diagnosys Espion 3 system with Ganzﬁeld bowl.
C57BL/6J mice (Charles River Laboratories) were dark-adapted over-
night prior to recordings. The mice were anesthetized by IP injec-
tion of 100−200 mg/kg ketamine and 20 mg/kg xylazine and placed
on a heating pad to maintain temperature throughout the recordings.
Pupils were dilated in both eyes by one drop of tropicamide. GelTal
(hypromellose) was applied to the eyes to ensure conduction to the
electrodes. The reference electrode (needle) was placed subcuta-
neously in the forehead and measuring electrodes (gold loops) were
placed on the corneas. For the stimulation, a series of white ﬂashes
were used at 0.0001, 0.001, 0.01, 0.1, and 5 cd-s/m2 intensities with
mice exposed to 5 ﬂashes per intensity with a 30 s recovery in between
each ﬂash. Electroretinograms were recorded with positive STR,
negative STR, for which a- and b-waves were analyzed. The STR
data shown in this paper were obtained under 0.001 cd-s/m2
ﬂash intensities while the a-wave and b-wave data were obtained for
0.1 cd-s/m2. These ﬂash intensities produced electroretinograms with
the best signal-to-noise ratio.
Immunohistochemistry and Confocal Imaging. Eyes from
euthanized mice were collected in PBS and ﬁxed in 4% PFA overnight.
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Retinas were carefully dissected under a microscope. Retinas were
blocked with 10% goat serum overnight at room temperature. Retinas
were then washed with 0.1% triton × 0.1% tween 20 in PBS three
times before incubation with anti-RBPMS-Rb-IgG (Abcam) and anti-
GFP-m-igG (Abcam) overnight at 4 °C. After they were washed three
times as described above, the retinas were incubated with antimouse-
Alexa647 and antirabit-Alexa488 1 h at room temperature. Lastly the
retinas were washed, incubated with 0.5 μg/mL DAPI in PBS for
1 min at room temperature, and washed again before mounting
on glass slides using 9% poly vinyl-alcohol, 22% glycerol, 2%
1,4-diazabicyclo[2.2.2]octane in 88 mM Tris-HCl, pH 8.5.
Slides were imaged on a Leica TCS SP5 confocal microscope using
a 40× oil emission objective. The predeﬁned settings for the dyes
used were chosen in the Leica software. Sequential scanning was used
to avoid spillover between the DAPI channel and the Alexa488 channel.
Retinas were imaged approximately 1 mm from the optic nerve head.
To quantify surviving host RGS, z-stacks of approximately 16 μm with
a step size of 0.5 μm were collected. Stacks were z-projected to form
one image in ImageJ. 2−3 images were obtained per retina. Surviving
RGCs were counted manually. To evaluate survival of transplanted
RGCs that might be heterogeneously distributed across the retina, the
whole retina was imaged using a Zeiss Axio Scan Z.1 slide scanner
(20× objective). Signals were recorded in the 488, 560, and 647 nm
channels. To eliminate some of the green autoﬂuorescence from the
retina, the signal from the 560 nm channel was subtracted from the
488 nm channel before counting the green cells in Zeiss Zen Blue and
Black lite software. Cells were counted manually.
Statistical Analysis. Statistical analysis was performed using
GraphPad Prism 7 software. The following statistical methods were
used to analyze the biological data: (Figure 2A) one-way ANOVA post
hoc Tukey HSD test; (Figure 2B) two-way ANOVA; (Figure 3A)
one-way ANOVA, no signiﬁcance; (Figure 3B) one-way ANOVA post
hoc Tukey HSD test; (Figure 3C) Kruskal−Wallis, no signiﬁcance;
(Figure 4D) one-way ANOVA post hoc Tukey HSD; (Figure 5A)
one-way ANOVA, no signiﬁcance; (Figure 5B) one-way ANOVA post
hoc Tukey HSD test; (Figure 5C) Kruskal−Wallis post hoc Dunn’s
test; (Figure 6A) One-way ANOVA post hoc Tukey HSD; (Figure 6B)
Unpaired t test, no signiﬁcance. The threshold of statistical signiﬁcance
(alpha) for all analyses was 0.05. Distribution curves and quantile−
quantile (Q−Q) plots were used to determine whether data sets were
parametric or nonparametric. Statistical signiﬁcance between healthy
control eyes and treated eyes was signiﬁcant and not shown for clarity.
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